Antinociception following implantation of mouse B16 melanoma cells in mouse and rat spinal cord

Hope H. Wu; Bruce R. Lester; Zhengqi Sun; George L. Wilcox

doi:10.1016/0304-3959(94)90095-7

Antinociception following implantation of mouse B16 melanoma cells in mouse and rat spinal cord

Hope H. Wu, Bruce R. Lester, Zhengqi Sun, George L. Wilcox

Neuroscience

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

B16 F1C29 melanoma cells, which are thought to contain and release catecholamines, were implanted in mouse and rat spinal subarachnoid space. B16 F1C29 cell implants augmented the antinociceptive effect of morphine in tail-flick test, and this interaction was blocked by either the α₂-adrenergic antagonist idazoxan or the opioid antagonist naloxone. B16 F1C29 cell implants also augmented the antinociceptive effect of the catecholamine re-uptake blocker desipramine. Substance P-induced biting and scratching behaviors were inhibited in mice receiving B16 F1C29 cell implants, and this effect of B16 F1C29 cell implants was blocked by the α₂-adrenergic antagonist idazoxan. Mice receiving B16 F1C29 cell implants showed tolerance to intrathecal administration of the α₂-adrenergic agonist UK 14304. These results suggest that B16 cell implant-induced antinociception was mediated by catecholamines secreted from the cell implants and acting at spinal α₂-adrenergic receptors. Spinal implantation of catecholamine-releasing cells may provide an alternative approach for the therapy of chronic intractable pain and a useful model to study α₂-adrenergic receptor tolerance.

Original language	English (US)
Pages (from-to)	203-210
Number of pages	8
Journal	Pain
Volume	56
Issue number	2
DOIs	https://doi.org/10.1016/0304-3959(94)90095-7
State	Published - Feb 1994

Bibliographical note

Funding Information:
This work was supported by National Institute of Drug Abuse (l-ROl-DA-01933, I-ROl-DA-04274 and l-K02-DA-00145) to G.L.W. We wish to thank Drs. Ping-Yee Law, Leonard Lichtblau, and Robert F. O’Dea for advice in the design and analysiso f these studies.

Keywords

Antinociception
B16 cell implantation
Catecholamine
Interaction
Spinal cord
Tolerance

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/0304-3959(94)90095-7

Find It

Find It at U of M Libraries

Cite this

@article{29523d4528ce4dcba11ee24a6cc3acea,

title = "Antinociception following implantation of mouse B16 melanoma cells in mouse and rat spinal cord",

abstract = "B16 F1C29 melanoma cells, which are thought to contain and release catecholamines, were implanted in mouse and rat spinal subarachnoid space. B16 F1C29 cell implants augmented the antinociceptive effect of morphine in tail-flick test, and this interaction was blocked by either the α2-adrenergic antagonist idazoxan or the opioid antagonist naloxone. B16 F1C29 cell implants also augmented the antinociceptive effect of the catecholamine re-uptake blocker desipramine. Substance P-induced biting and scratching behaviors were inhibited in mice receiving B16 F1C29 cell implants, and this effect of B16 F1C29 cell implants was blocked by the α2-adrenergic antagonist idazoxan. Mice receiving B16 F1C29 cell implants showed tolerance to intrathecal administration of the α2-adrenergic agonist UK 14304. These results suggest that B16 cell implant-induced antinociception was mediated by catecholamines secreted from the cell implants and acting at spinal α2-adrenergic receptors. Spinal implantation of catecholamine-releasing cells may provide an alternative approach for the therapy of chronic intractable pain and a useful model to study α2-adrenergic receptor tolerance.",

keywords = "Antinociception, B16 cell implantation, Catecholamine, Interaction, Spinal cord, Tolerance",

author = "Wu, {Hope H.} and Lester, {Bruce R.} and Zhengqi Sun and Wilcox, {George L.}",

note = "Funding Information: This work was supported by National Institute of Drug Abuse (l-ROl-DA-01933, I-ROl-DA-04274 and l-K02-DA-00145) to G.L.W. We wish to thank Drs. Ping-Yee Law, Leonard Lichtblau, and Robert F. O{\textquoteright}Dea for advice in the design and analysiso f these studies.",

year = "1994",

month = feb,

doi = "10.1016/0304-3959(94)90095-7",

language = "English (US)",

volume = "56",

pages = "203--210",

journal = "Pain",

issn = "0304-3959",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Antinociception following implantation of mouse B16 melanoma cells in mouse and rat spinal cord

AU - Wu, Hope H.

AU - Lester, Bruce R.

AU - Sun, Zhengqi

AU - Wilcox, George L.

N1 - Funding Information: This work was supported by National Institute of Drug Abuse (l-ROl-DA-01933, I-ROl-DA-04274 and l-K02-DA-00145) to G.L.W. We wish to thank Drs. Ping-Yee Law, Leonard Lichtblau, and Robert F. O’Dea for advice in the design and analysiso f these studies.

PY - 1994/2

Y1 - 1994/2

N2 - B16 F1C29 melanoma cells, which are thought to contain and release catecholamines, were implanted in mouse and rat spinal subarachnoid space. B16 F1C29 cell implants augmented the antinociceptive effect of morphine in tail-flick test, and this interaction was blocked by either the α2-adrenergic antagonist idazoxan or the opioid antagonist naloxone. B16 F1C29 cell implants also augmented the antinociceptive effect of the catecholamine re-uptake blocker desipramine. Substance P-induced biting and scratching behaviors were inhibited in mice receiving B16 F1C29 cell implants, and this effect of B16 F1C29 cell implants was blocked by the α2-adrenergic antagonist idazoxan. Mice receiving B16 F1C29 cell implants showed tolerance to intrathecal administration of the α2-adrenergic agonist UK 14304. These results suggest that B16 cell implant-induced antinociception was mediated by catecholamines secreted from the cell implants and acting at spinal α2-adrenergic receptors. Spinal implantation of catecholamine-releasing cells may provide an alternative approach for the therapy of chronic intractable pain and a useful model to study α2-adrenergic receptor tolerance.

AB - B16 F1C29 melanoma cells, which are thought to contain and release catecholamines, were implanted in mouse and rat spinal subarachnoid space. B16 F1C29 cell implants augmented the antinociceptive effect of morphine in tail-flick test, and this interaction was blocked by either the α2-adrenergic antagonist idazoxan or the opioid antagonist naloxone. B16 F1C29 cell implants also augmented the antinociceptive effect of the catecholamine re-uptake blocker desipramine. Substance P-induced biting and scratching behaviors were inhibited in mice receiving B16 F1C29 cell implants, and this effect of B16 F1C29 cell implants was blocked by the α2-adrenergic antagonist idazoxan. Mice receiving B16 F1C29 cell implants showed tolerance to intrathecal administration of the α2-adrenergic agonist UK 14304. These results suggest that B16 cell implant-induced antinociception was mediated by catecholamines secreted from the cell implants and acting at spinal α2-adrenergic receptors. Spinal implantation of catecholamine-releasing cells may provide an alternative approach for the therapy of chronic intractable pain and a useful model to study α2-adrenergic receptor tolerance.

KW - Antinociception

KW - B16 cell implantation

KW - Catecholamine

KW - Interaction

KW - Spinal cord

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=0028158730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028158730&partnerID=8YFLogxK

U2 - 10.1016/0304-3959(94)90095-7

DO - 10.1016/0304-3959(94)90095-7

M3 - Article

C2 - 7516533

AN - SCOPUS:0028158730

SN - 0304-3959

VL - 56

SP - 203

EP - 210

JO - Pain

JF - Pain

IS - 2

ER -

Antinociception following implantation of mouse B16 melanoma cells in mouse and rat spinal cord

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this